Key Takeaways
- Bayer Crop Science reported Q2 2026 sales up 3.5% (currency- and portfolio-adjusted) to 4.910 billion euros.
- Divisional EBITDA before special items jumped 30.2% to 902 million euros, lifting the margin 3.9 points to 18.4%.
- Soybean Seed and Traits sales rose 16.9% and Cotton Seed 69.2% after the return of the dicamba label in the United States.
- Glyphosate-based herbicides grew 12.6% and insecticides 15.9%, led by Europe, the Middle East and Africa.
- Bayer confirmed its currency-adjusted full-year outlook and now expects lower net financial debt of 29 to 30 billion euros.
Bayer’s agricultural business drove the group’s second quarter, with Crop Science sales rising 3.5% on a currency- and portfolio-adjusted basis to 4.910 billion euros and divisional earnings climbing sharply. The German company reported the results alongside its Half-Year Financial Report on August 4.
Bayer Crop Science Drives the Quarter
EBITDA before special items at Bayer Crop Science advanced 30.2% to 902 million euros, and the division’s margin on that basis rose 3.9 percentage points to 18.4%. Bayer attributed the gains to high-margin topline growth and a lower cost of goods sold from efficiency programs under its Five-Year Framework. “Operationally, we’re well on track to achieve our full-year outlook,” said Bill Anderson, CEO of Bayer, who cited continued execution of the framework to improve Crop Science profitability.
Seeds and Traits: A Dicamba Boost
Sales at Soybean Seed and Traits rose 16.9% and Cotton Seed jumped 69.2% (currency- and portfolio-adjusted), both helped by the return of the dicamba label in the United States. Corn Seed and Traits sales fell 2.5%, as substantial gains in Europe/Middle East/Africa and Asia/Pacific only partly offset lower volumes in North America, where business was affected by volume phasing into the first quarter.
Bayer Crop Science Lifts Crop Protection Sales
In crop protection, Bayer’s glyphosate-based herbicides grew 12.6% on higher volumes and prices, especially in Europe/Middle East/Africa. Insecticide sales rose 15.9%, again driven mainly by higher volumes and prices in Europe/Middle East/Africa and Asia/Pacific.
Group Results and Outlook
Group sales rose 2.2% (adjusted) to 10.872 billion euros, and EBITDA before special items increased 1.9% to 2.144 billion euros. Net income improved to 219 million euros from a loss a year earlier, though core earnings per share fell 16.7% to 0.95 euros. Pharmaceuticals sales held roughly level while Consumer Health edged up. Bayer confirmed its currency-adjusted full-year guidance and now expects net financial debt of 29 to 30 billion euros, below its earlier forecast.
